Clobazam

Clobazam
Clinical data
Trade namesFrisium, Onfi, others
Other namesClobazepam
AHFS/Drugs.comMonograph
MedlinePlusa612008
License data
Pregnancy
category
  • AU: C
Dependence
liability
High
Addiction
liability
High
Routes of
administration
By mouth, sublingual
Drug classBenzodiazepine, Anticonvulsant
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityRapidly and extensively absorbed; 87%–95% (oral)
Protein binding80–90%
MetabolismLiver
Metabolites
    • • N-desmethylclobazam
      (Norclobazam, 4-oxo-Lofendazam)
    • • N-desmethylclobazam-3',4'-dihydrodiol
    • • 9-Hydroxy-N-desmethylclobazam
    • • 4'-Hydroxy-N-desmethylclobazam
    • • 4'-Hydroxyclobazam
Onset of action0.5–4 hours
Elimination half-life
    • • Clobazam: 36–42 hours
    • N-desmethylclobazam: 71–82 hours
Excretion
Identifiers
  • 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.040.810
Chemical and physical data
FormulaC16H13ClN2O2
Molar mass300.74 g·mol−1
3D model (JSmol)
  • ClC1=CC(N(C2=CC=CC=C2)C(CC(N3C)=O)=O)=C3C=C1
  • InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3
  • Key:CXOXHMZGEKVPMT-UHFFFAOYSA-N

Clobazam, sold under the brand names Frisium and Onfi, among others, is a long-acting benzodiazepine medication primarily used as an anxiolytic and anticonvulsant. Clobazam is a 1,5-benzodiazepine with unique pharmacological characteristics that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. It was approved in Australia in 1970 and France in 1974 for short-term anxiety management. Clobazam is solely approved for use in the United States as a treatment for Lennox–Gastaut syndrome, but the drug is available in other countries as an anti-anxiety agent for the short-term treatment of persistent and debilitating forms of anxiety. It has shown a distinct profile and addictive potential compared to the more common benzodiazepines. Clobazam is the only 1,5‑benzodiazepine that has been marketed for clinical use, making it the sole representative of this structural class of benzodiazepines.

The drug has been approved by Health Canada as an add-on therapy for generalized tonic–clonic, myoclonic, and focal impaired awareness seizures.

In 2011, Lundbeck markets the drug in the United States as Onfi, an adjunctive therapy for seizures associated with Lennox–Gastaut syndrome in patients who are at least two years old.